Latest news with #RemsimaSC
Korea Herald
5 days ago
- Business
- Korea Herald
Celltrion's Remsima SC hits fivefold growth in Europe
South Korean biopharmaceutical firm Celltrion announced Wednesday that the market share of Remsima SC, the subcutaneous formulation of the autoimmune disease treatment infliximab, has quintupled across Europe over just four years. According to the company, citing global pharmaceutical market research firm IQVIA, Remsima SC captured a 22 percent market share as of last year, surging from 4 percent in 2021 following its debut in 2020. When combined with the share of Remsima, the intravenous version, Celltrion's Remsima product line commanded a 71 percent market share in Europe. Celltrion noted that Remsima SC's success in Europe bodes well for the US market, given that its recent inclusion of Zymfentra — another brand name for Remsima SC in the US — in major US insurance formularies is expected to drive accelerated adoption. Celltrion's other autoimmune treatments are also making significant inroads in Europe. Yuflyma, its adalimumab-aaty biosimilar, secured a 21 percent market share last year. Meanwhile, its ustekinumab biosimilar, Steqeyma, launched in Europe in October, captured more than 2 percent market share within just a few months. 'Remsima SC's growing presence in Europe can be attributed to its convenience, treatment efficacy and tailored sales strategies from our local subsidiaries,' a Celltrion official said. 'With our existing products leading prescriptions in Europe, we plan to continue our growth through the launch of new biosimilars during the remainder of the year.'
Hans India
21-05-2025
- Business
- Hans India
S. Korea's Celltrion expects limited impact from US executive order on price reduction
Seoul: Celltrion, a leading South Korean biopharmaceutical company, on Wednesday said it expects limited impact from recent US policy developments stemming from a drug pricing executive order signed by President Donald Trump. Last week, Trump announced an executive order introducing a most-favoured nation (MFN) pricing model, intended to align US drug prices with the lowest prices paid by peer nations, Yonhap news agency reported. The US Department of Health and Human Services released follow-up details on Tuesday, setting the MFN target price at the lowest drug price found in an Organization for Economic Co-operation and Development (OECD) country with a gross domestic product (GDP) per capita of at least 60 percent of that of the United States. "This announcement targets high-cost medicines," Celltrion said. "The impact on Celltrion's products is expected to be limited, as biosimilars, already available at lower prices and helping reduce drug costs through competition, are not included in the scope of this measure," the company added. It said the MFN pricing rule will provide an opportunity for biosimilars in the long run as it helps the US drug market become more competitive. Under the current US pharmacy benefit manager (PBM) system, original biologic drugs are typically given priority in formularies, limiting biosimilar adoption. Celltrion noted that its autoimmune disease treatment, Remsima SC, is unlikely to fall under the MFN pricing rule, as it is classified as an original biologic in the US but a biosimilar in other countries, while the MFN pricing model seeks to compare the US price of an original drug with its overseas price. The company pledged to respond swiftly to global regulatory shifts while continuing to grow its business. In 2024, Celltrion posted 3.56 trillion won ($2.57 billion) in sales.
Korea Herald
09-05-2025
- Business
- Korea Herald
Celltrion logs strongest Q1 sales
South Korean biopharmaceutical firm Celltrion reported record first-quarter revenue and a sharp jump in profit, as robust global demand for its next-generation biosimilars improved margins. Operating profit soared a whopping 870 percent from a year earlier to 149.4 billion won ($107 million) in the January-March period, while consolidated revenue rose 14.2 percent to 841.9 billion won, the South Korean biopharmaceutical firm said Friday. The earnings boost was attributed to the end of amortization costs tied to past mergers, enhanced inventory management and strong performance from high-margin products. Sales of key biosimilars, including Remsima SC, Yuflyma and Vegzelma, climbed more than 62 percent from a year earlier. Yuflyma, a treatment for autoimmune diseases, posted more than 100 billion won in quarterly sales for the first time, rising 1.6 times year-on-year. Vegzelma, a cancer treatment, secured a 28 percent prescription share in Europe's oncology biosimilar market, despite its relatively late market entry. Celltrion plans to launch four new high-margin biosimilars in the second half of the year and begin full-scale production of titer-enhanced products. The company expects revenue from new and follow-up therapies to make up over 60 percent of total sales by year-end. In drug development, Celltrion's multispecific antibody CT-P72 demonstrated strong tumor suppression and low toxicity in preclinical studies presented at the 2025 American Association for Cancer Research meeting. 'We've laid the groundwork for both quantitative and qualitative growth this year through strong performance from our next-generation biosimilars and cost-efficiency gains,' a company official said. 'With upcoming product launches and a solid new drug pipeline, we will continue to focus efforts on sustained growth.'
Korea Herald
26-02-2025
- Business
- Korea Herald
Celltrion's Remsima hits W1.2tr sales milestone
Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it the first product in Korean biopharmaceutical history to exceed the 1 trillion won global sales milestone. The biosimilar giant reported annual sales of 3.55 trillion won last year and an operating profit of 492 billion won. Its flagship product, Remsima, contributed 1.26 trillion won, making up around 35.6 percent of total sales, the company revealed on Wednesday. After its European launch in September 2013, Remsima achieved a 52 percent market share by the end of 2017, according to pharmaceutical market research firm IQVIA, overtaking the original product's market share for the first time among antibody biosimilars. In 2022, it also set a milestone as the first developed drug in Korea to receive regulatory approval in over 100 countries. Through its 40 overseas subsidiaries, Celltrion directly distributes pharmaceuticals and executes tailored sales strategies for each country. Meanwhile, the rapid growth of Remsima SC, the world's only subcutaneous formulation of infliximab, is also attracting considerable market attention. When Remsima SC was introduced in Europe in 2020, its market share was just 1 percent, but by the third quarter of last year, it had risen significantly to 21 percent, according to the company. Last year, Remsima SC was launched in the US under the brand name Zymfentra, and successfully set the stage for expanding prescriptions by securing listing agreements with three major pharmacy benefit managers controlling 80 percent of the country's insurance market. 'We will accelerate the launch of follow-up biosimilars, including Remsima SC, and continue pursuing successful new drug development in areas such as antibody-drug conjugates and multi-specific antibodies, aiming to create the second and third 'Remsima,'' a Celltrion official said.
Korea Herald
20-02-2025
- Business
- Korea Herald
Celltrion, CJ Bioscience strengthen European presence at ECCO'25
Celltrion and CJ Bioscience are set to showcase their global competitiveness through research findings at the 2025 European Crohn's and Colitis Organization congress, one of the world's most prestigious inflammatory bowel disease research gatherings, which kicked off Thursday in Berlin. As Europe's largest IBD conference, ECCO draws over 8,000 medical professionals annually from around the world, including North America and Asia. The four-day event serves as a key platform for discussions on cutting-edge clinical research and emerging treatment approaches. Celebrating its 20th anniversary, this year's conference is themed 'Sustainability in IBD and Beyond.' As the only Korean company participating as an official sponsor, Celltrion is aiming to make a strong impact with a dedicated booth showcasing scientific programs. The company is set to present research findings on the treatment outcomes of moderate to severe ulcerative colitis patients using Remsima SC. Additionally, Celltrion will unveil three poster presentations, covering clinical recovery time after dose escalation in patients with loss of response, the efficacy of maintenance therapy based on disease location in Crohn's disease patients, and the impact of immunogenicity in two-year clinical data from Crohn's disease patients. 'The newly presented research data is expected to further strengthen the preference for Remsima SC,' a Celltrion official said. 'It will not only reinforce our position in Europe but also enhance trust in our products in key regions such as the US, Asia and Latin America, where we are preparing for prescription expansion and new product launches.' According to market research firm IQVIA, Remsima SC has captured 25 percent of the market share across five major European countries -- Germany, Spain, the UK, Italy and France, as of the third quarter of 2024. When combined with the intravenous formulation of Remsima, the overall market share across these EU nations reaches 79 percent. Meanwhile, marking its first-ever participation at ECCO, CJ Bioscience is unveiling its latest research findings on CJRB-201, a promising microbiome-based drug candidate developed through Ez-Mx, an AI-powered drug discovery platform. The company will present new data on the drug's anti-inflammatory effects and mechanism of action, backed by immune analysis and animal studies. "While antibody-based therapies are often challenging to administer and lack sustained safety, CJRB-201 is designed to offer superior safety and enhanced usability for prolonged treatment," a CJ Bioscience official said, adding that the company is preparing to initiate clinical development next year.
